menu

Principles and Practice Strategies for Immunotherapy in Genitourinary Malignancies

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Principles and Practice Strategies for Immunotherapy in Genitourinary Malignancies

close
1.00 credits
60 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage metastatic UC and RCC. Given the approval of immune checkpoint inhibitors for the treatment of metastatic UC and RCC in recent years, and more emerging evidence, it can be challenging to understand how to best incorporate these therapies into current treatment strategies.

    This activity will review the latest clinical advances, emerging data, and guideline recommendations for immunotherapy for the treatment of advanced renal cell carcinoma and urothelial carcinoma.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Assess evidence supporting the use of immune checkpoint inhibitors for the first-line treatment of advanced or metastatic urothelial carcinoma and renal cell carcinoma
    2. Analyze the role of first-line maintenance treatment with immune checkpoint inhibitors in metastatic urothelial carcinoma
    3. Compare survival data for sequential immunotherapy and standard of care chemotherapy in the first-line treatment of metastatic urothelial carcinoma
    4. Develop evidence-based treatment sequencing strategies with immune checkpoint inhibitors for the first-line and subsequent treatment of advanced or metastatic urothelial carcinoma and renal cell carcinoma
  • Target Audience

    This activity is intended for medical oncologists, urologists, surgeons, pharmacists, physician assistants, oncology nurses, and other healthcare professionals involved in the treatment of genitourinary cancers.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires instructors, planners, managers, reviewers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Yohann Loriot, MD, PhD, reported a financial interest/relationship or affiliation in the form of Received income in any amount from: Janssen Oncology; Sanofi; AstraZeneca Pharmaceuticals LP; Immunomedics, Inc; Astellas Pharma US, Inc; Seattle Genetics, Inc; Roche; Bristol-Myers Squibb Co; and Merck Sharp & Dohme. Contracted research: Janssen Oncology and Celsius Therapeutics. Robert J. Motzer, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Pfizer, Inc; Eisai Inc; Exelixis, Inc; Novartis Pharmaceuticals Corp; Merck & Co, Inc; Incyte Corp; Eli Lilly and Co; Roche; and Genentech, Inc.

    The planners, managers and reviewers reported the following financial relationships or relationships they or their spouse/life partner  have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC;  and Adrienne N. Nedved, MPA, PharmD, BCOP; hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck & Co.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    Accreditation Statement

    ReachMD Healthcare ImageIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    ReachMD Healthcare ImageThis activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ReachMD Healthcare ImageCredit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 01/06/2022. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-20-077-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)

    Provided by ReachMD Healthcare Image

  • Commercial Support

    This activity is supported by an educational grant from Pfizer Inc. and EMD Serono, Inc.

  • Terms of Use

    Disclosure of Unlabeled Use    
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:  
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Advances in immune checkpoint inhibitor therapy are transforming the way clinicians treat and manage metastatic UC and RCC. Given the approval of immune checkpoint inhibitors for the treatment of metastatic UC and RCC in recent years, and more emerging evidence, it can be challenging to understand how to best incorporate these therapies into current treatment strategies.

    This activity will review the latest clinical advances, emerging data, and guideline recommendations for immunotherapy for the treatment of advanced renal cell carcinoma and urothelial carcinoma.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Assess evidence supporting the use of immune checkpoint inhibitors for the first-line treatment of advanced or metastatic urothelial carcinoma and renal cell carcinoma
    2. Analyze the role of first-line maintenance treatment with immune checkpoint inhibitors in metastatic urothelial carcinoma
    3. Compare survival data for sequential immunotherapy and standard of care chemotherapy in the first-line treatment of metastatic urothelial carcinoma
    4. Develop evidence-based treatment sequencing strategies with immune checkpoint inhibitors for the first-line and subsequent treatment of advanced or metastatic urothelial carcinoma and renal cell carcinoma
  • Target Audience

    This activity is intended for medical oncologists, urologists, surgeons, pharmacists, physician assistants, oncology nurses, and other healthcare professionals involved in the treatment of genitourinary cancers.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires instructors, planners, managers, reviewers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Yohann Loriot, MD, PhD, reported a financial interest/relationship or affiliation in the form of Received income in any amount from: Janssen Oncology; Sanofi; AstraZeneca Pharmaceuticals LP; Immunomedics, Inc; Astellas Pharma US, Inc; Seattle Genetics, Inc; Roche; Bristol-Myers Squibb Co; and Merck Sharp & Dohme. Contracted research: Janssen Oncology and Celsius Therapeutics. Robert J. Motzer, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Pfizer, Inc; Eisai Inc; Exelixis, Inc; Novartis Pharmaceuticals Corp; Merck & Co, Inc; Incyte Corp; Eli Lilly and Co; Roche; and Genentech, Inc.

    The planners, managers and reviewers reported the following financial relationships or relationships they or their spouse/life partner  have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC;  and Adrienne N. Nedved, MPA, PharmD, BCOP; hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck & Co.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    Accreditation Statement

    ReachMD Healthcare ImageIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    ReachMD Healthcare ImageThis activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ReachMD Healthcare ImageCredit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 01/06/2022. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-20-077-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)

    Provided by ReachMD Healthcare Image

  • Commercial Support

    This activity is supported by an educational grant from Pfizer Inc. and EMD Serono, Inc.

  • Terms of Use

    Disclosure of Unlabeled Use    
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:  
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 9/19/21